<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620903</url>
  </required_header>
  <id_info>
    <org_study_id>ECWM-2</org_study_id>
    <secondary_id>2017-004362-95</secondary_id>
    <nct_id>NCT03620903</nct_id>
  </id_info>
  <brief_title>Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia</brief_title>
  <official_title>Efficacy of First Line Bortezomib, Rituximab, Ibrutinib (B-RI) for Patients With Treatment Naive Waldenström's Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Buske</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinAssess</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zentrum für Klinische Studien Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Waldenström macroglobulinemia (WM) conventional chemotherapy induces only low complete&#xD;
      remission (CR) rates and responses of short duration compared to other indolent lymphomas.&#xD;
      Thus innovative approaches are needed which combine excellent activity and tolerability in&#xD;
      patients with WM, who are mostly of advanced age. The immunochemotherapy DRC (dexamethasone,&#xD;
      rituximab, cyclophosphamide) was shown to be highly effective in patients with WM without&#xD;
      inducing major hematological toxicities. On the other hand the proteasome inhibitor&#xD;
      bortezomib showed substantial activity as a single agent in WM with only very few side&#xD;
      effects when given in a weekly schedule. Recent data confirmed high activity with low&#xD;
      toxicity for ibrutinib in relapsed WM patients as single agent therapy. Based on these&#xD;
      observations it is the aim of this study to investigate the efficacy and toxicity of the&#xD;
      chemotherapy-free combination bortezomib, rituximab, ibrutinib (B-RI) in treatment naïve WM&#xD;
      patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Waldenström's macroglobulinemia (WM) conventional chemotherapy induces only low complete&#xD;
      remission (CR) rates and responses of short duration compared to other indolent lymphomas.&#xD;
      Thus innovative approaches are needed which combine excellent activity and tolerability in&#xD;
      patients with WM, who are mostly of advanced age. Today, chemotherapy in combination with the&#xD;
      anti-cluster of differentiation (CD) 20 antibody rituximab is still the backbone of treatment&#xD;
      in patients with WM and is recommended as first line in national and international treatment&#xD;
      guidelines. With the approval of Ibrutinib by the European Medicines Agency (EMA) 2015 for&#xD;
      patients with relapsed WM or for patients not eligible for chemotherapy with treatment naïve&#xD;
      WM treatment landscape has changed in this lymphoma subtype and there is an urgent need to&#xD;
      evaluate to which extent chemotherapy-free approaches add clinical benefit to the patient.&#xD;
      The treatment in the &quot;European Consortium for Waldenström's Macroglobulinemia&quot; (ECWM)-2 trial&#xD;
      will test, whether the chemotherapy-free approach, which is given orally (ibrutinib) and&#xD;
      subcutaneously (bortezomib and rituximab from cycle 2 onwards) (B-RI) will approach the&#xD;
      efficacy of chemotherapy containing treatment concepts, but avoids chemotherapy associated&#xD;
      toxicity. From the perspective of single agent ibrutinib, this regimen tests whether&#xD;
      ibrutinib can be further optimized by adding rituximab and bortezomib. The combination of&#xD;
      rituximab and ibrutinib was tested in comparison to rituximab/placebo in a large&#xD;
      international phase III trial on behalf of the European Consortium for Waldenström's&#xD;
      Macroglobulinemia in relapsed and first line WM, and results were recently published: in this&#xD;
      trial no unexpected toxicity of the combination ibrutinib/rituximab was reported.&#xD;
      Furthermore, ibrutinib/rituximab was significantly superior to rituximab/placebo with regard&#xD;
      to response rates and PFS. From the perspective of the established rituximab/bortezomib&#xD;
      regimen, the combination of B-RI will evaluate whether adding ibrutinib to this combination&#xD;
      will add any benefit for the patient.&#xD;
&#xD;
      To this end, the aim of the study is to assess the toxicity and efficacy of B-RI in an&#xD;
      exploratory phase II trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint is the rate of 1 year progression free survival (1YPFS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months</time_frame>
    <description>response rates (CR, VGPR, PR, MR) and overall response rate (CR, VGPR, PR, MR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>up to 10 years</time_frame>
    <description>At least achieving a MR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to best response</measure>
    <time_frame>up to 10 years</time_frame>
    <description>time from the start of induction to best response the patient achieves (CR, VGPR, PR, MR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first response</measure>
    <time_frame>up to 10 years</time_frame>
    <description>time from the start of induction to first response (MR, PR, VGPR or CR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment failure (TTF)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>time of start of induction treatment to discontinuation of therapy for any reason including death from any cause, progression, toxicity or add-on of new anti-cancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission duration (RD)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>patients with response (CR, VGPR, PR, MR) from the date of response to the date of progression, relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>date of start of treatment to the following events: the date of progression and the date of death if it occurred earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause specific survival (CSS)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>period from the start of induction treatment to death from lymphoma or lymphoma related cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>period from the start of induction treatment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analysis</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Safety including treatment associated adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Bortezomib-Rituximab-Ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1:&#xD;
Rituximab: 375 mg/m2 intravenously (i.v) day 1; Bortezomib:1.6 mg/ m2 subcutanously (SC) day 1,8,15; Ibrutinib: 420 mg orally (p.o.) day 1-28;&#xD;
Cycle 2-6 Rituximab: 1400 mg absolute SC day 1; Bortezomib:1.6 mg/ m2 SC day 1,8,15; Ibrutinib: 420 mg p.o. day 1-28;&#xD;
Maintenance I (1 cycle = 56 days):&#xD;
Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years); Rituximab 1400 mg absolute SC day 1, every second month for 24 months (month 7-30);&#xD;
Maintenance II (1 cycle = 84 days):&#xD;
Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years);</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib / Bortezomib / Rituximab</intervention_name>
    <description>Induction (Rituximab / Bortezomib / Ibrutinib), Maintenance I (Ibrutinib / Rituximab), Maintenance II (Ibrutinib)</description>
    <arm_group_label>Bortezomib-Rituximab-Ibrutinib</arm_group_label>
    <other_name>Imbruvica / Velcade / Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Clinicopathological diagnosis of WM as defined by consensus panel one of the Second&#xD;
             International Workshop on WM, diagnosed by a reference pathology center. Pathological&#xD;
             diagnosis has to occur before study inclusion. In addition, pathological specimens&#xD;
             have to be sent to the national pathological reference center at study inclusion. The&#xD;
             positivity for Cluster of Differentiation (CD) 20 can be assumed from any previous&#xD;
             bone marrow immunohistochemistry or flow cytometry analysis performed up to 6 months&#xD;
             prior to enrollment. Inclusion in the study will be based on morphological and&#xD;
             immunological criteria. Immunophenotyping will be performed in each center and saved&#xD;
             locally. Flow cytometry of bone marrow and blood cells will include at least one&#xD;
             double staining and assess the expression of the following antigens: surface&#xD;
             immunoglobulin, CD19, CD20, CD5, CD10 and CD23. Patients are eligible if tumor cells&#xD;
             express the following antigens: CD19, CD20, and if they are negative for CD5, CD10 and&#xD;
             CD23 expression. Patients with tumor cells positive for CD5 and/or CD23 and&#xD;
             morphologically similar to WM cells may be included after ruling out other low-grade&#xD;
             B-cell malignancies.&#xD;
&#xD;
          -  Presence of at least one criterion for initiation of therapy, according to the 2nd&#xD;
             Workshop on WM:&#xD;
&#xD;
               -  Recurrent fever, night sweats, weight loss, fatigue (at least one of them)&#xD;
&#xD;
               -  Hyperviscosity&#xD;
&#xD;
               -  Lymphadenopathy which is either symptomatic or bulky (≥5 cm in maximum diameter)&#xD;
&#xD;
               -  Symptomatic hepatomegaly and/or splenomegaly&#xD;
&#xD;
               -  Symptomatic organomegaly and/or organ or tissue infiltration&#xD;
&#xD;
               -  Peripheral neuropathy due to WM&#xD;
&#xD;
               -  Symptomatic cryoglobulinemia&#xD;
&#xD;
               -  Cold agglutinin anemia&#xD;
&#xD;
               -  Immunoglobulin M (IgM) related immune hemolytic anemia and/or thrombocytopenia&#xD;
&#xD;
               -  Nephropathy related to WM&#xD;
&#xD;
               -  Amyloidosis related to WM&#xD;
&#xD;
               -  Hemoglobin ≤10g/dL&#xD;
&#xD;
               -  Platelet count &lt;100x109/L&#xD;
&#xD;
               -  Serum monoclonal protein &gt;5g/dL, even with no overt clinical symptoms&#xD;
&#xD;
          -  Low or absent IgG serum levels&#xD;
&#xD;
          -  World Health Organization (WHO)/Eastern Co-operative Oncology Group (ECOG) performance&#xD;
             status 0 to 2.&#xD;
&#xD;
          -  Other criteria:&#xD;
&#xD;
               -  Age ≥ than 18 years&#xD;
&#xD;
               -  Life expectancy &gt;3 months.&#xD;
&#xD;
               -  Baseline platelet count &gt;100x10exponential (E)9/L if not due to bone marrow (BM)&#xD;
                  involvement by the lymphoma, independent of any transfusions&#xD;
&#xD;
               -  absolute neutrophil count &gt;1x10E9/L independent of growth factor support.&#xD;
&#xD;
               -  Meet the following pretreatment laboratory criteria at the Screening visit&#xD;
                  conducted within 28 days of study enrollment:&#xD;
&#xD;
                    -  aspartate aminotransferase (AST): &lt;3 times the upper limit of institutional&#xD;
                       laboratory normal value&#xD;
&#xD;
                    -  alanine aminotransferase (ALAT): &lt;3 times the upper limit of institutional&#xD;
                       laboratory normal value&#xD;
&#xD;
                    -  Total Bilirubin: &lt; 1.5 times the upper limit of institutional laboratory&#xD;
                       normal value, unless clearly related to the disease (except if due to&#xD;
                       Gilbert's syndrome)&#xD;
&#xD;
                    -  Serum creatinine: ≤ 2 times the upper limit of institutional laboratory&#xD;
                       normal value or estimated Glomerular Filtration Rate (cockroft-gault ≥ 40&#xD;
                       mL/min/1.73m2)&#xD;
&#xD;
          -  Premenopausal fertile females must agree to use a highly effective method of birth&#xD;
             control for the duration of the therapy up to 6 months after end of therapy. A highly&#xD;
             effective method of birth control is defined as those which result in a low failure&#xD;
             rate (i.e. less than 1% per year) when used consistently and correctly such as&#xD;
             implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs),&#xD;
             sexual abstinence or vasectomised partner.&#xD;
&#xD;
          -  Men must agree not to father a child for the duration of therapy and 12 months after&#xD;
             and must agree to advice a female partner to use a highly effective method of birth&#xD;
             control.&#xD;
&#xD;
          -  Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care.&#xD;
&#xD;
          -  Affiliation to a social security scheme (relevant for France only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic treatment of the WM (plasmapheresis and short - term administration of&#xD;
             corticosteroids &lt; 4 weeks administered at a dose equivalent to &lt; 20 mg/day prednisone&#xD;
             is allowed)&#xD;
&#xD;
          -  Patient with hypersensitivity to Bortezomib&#xD;
&#xD;
          -  Patient with hypersensitivity to MabThera&#xD;
&#xD;
          -  Patient with hypersensitivity to Ibrutinib&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
          -  Uncontrolled viral infection&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or&#xD;
             active Hepatitis B Virus infection or any uncontrolled active systemic infection&#xD;
             requiring intravenous (IV) antibiotics.&#xD;
&#xD;
          -  Congenital or acquired severe immunodeficiency not attributed to lymphoma (clinical&#xD;
             appearance: recurrent infections, necessity of immunoglobulin substitution therapy,&#xD;
             patients after transplantation)&#xD;
&#xD;
          -  Known interstitial lung disease&#xD;
&#xD;
          -  Prior allergic reaction or severe anaphylactic reaction related to humanized or murine&#xD;
             monoclonal antibody.&#xD;
&#xD;
          -  Central Nervous System involvement by lymphoma&#xD;
&#xD;
          -  Prior history of malignancies unless the subject has been free of the disease for ≥ 5&#xD;
             years. Exceptions include the following:&#xD;
&#xD;
          -  Basal cell carcinoma of the skin,&#xD;
&#xD;
          -  Squamous cell carcinoma of the skin,&#xD;
&#xD;
          -  Carcinoma in situ of the cervix,&#xD;
&#xD;
          -  Carcinoma in situ of the breast,&#xD;
&#xD;
          -  Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b).&#xD;
&#xD;
          -  Uncontrolled illness including, but not limited to:&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (as indicated by metabolic derangements and/or severe&#xD;
             diabetes mellitus related uncontrolled organ complications)&#xD;
&#xD;
          -  Chronic symptomatic congestive heart failure (Class New York Heart Association (NYHA)&#xD;
             III or IV).&#xD;
&#xD;
          -  Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6&#xD;
             months&#xD;
&#xD;
          -  Clinically significant cardiac arrhythmia that is symptomatic or requires treatment,&#xD;
             or asymptomatic sustained ventricular tachycardia.&#xD;
&#xD;
          -  Known pericardial disease&#xD;
&#xD;
          -  acute diffuse infiltrative pulmonary and pericardial disease&#xD;
&#xD;
          -  Subjects with ≥ Grade 2 neuropathy.&#xD;
&#xD;
          -  Recent major surgery (within 4 weeks prior to study inclusion)&#xD;
&#xD;
          -  History of stroke or intracranial haemorrhage within 6 months prior to study inclusion&#xD;
&#xD;
          -  Women who are pregnant as well as women who are breast-feeding and do not consent to&#xD;
             discontinue breast-feeding.&#xD;
&#xD;
          -  Participation in another clinical trial within four weeks prior to study inclusion&#xD;
&#xD;
          -  No consent for registration, storage and processing of the individual&#xD;
             disease-characteristics and course as well as information of the family physician&#xD;
             about study participation&#xD;
&#xD;
          -  St. John's Wort with Ibrutinib&#xD;
&#xD;
          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg,&#xD;
             phenprocoumon).&#xD;
&#xD;
          -  Requires treatment with strong cytochrome P (CYP) 3A inhibitors.&#xD;
&#xD;
          -  Vaccinated with live, attenuated vaccines within 4 weeks prior to study inclusion.&#xD;
&#xD;
          -  Person of legal age who is incapable of comprehending the nature, significance and&#xD;
             implications of the clinical trial and of determining his/her will in the light of&#xD;
             these facts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Buske, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dajana Kaszynski</last_name>
    <phone>+4973150065833</phone>
    <email>studien.gla@uniklinik-ulm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helios Klinikum Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Fuhrmann, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studiengesellschaft Onkologie Bielefeld GbR</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Düwel, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DIAKO Ev. Diakonie-Krankenhaus gGmbH, Med. Klinik II</name>
      <address>
        <city>Bremen</city>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Ulrich Trappe, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle, Klinik für Innere Medizin IV</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Weber, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis, FÄ f. innere Medizin Hämatologie/Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Jentsch-Ullrich, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universtätsmedizin Mannheim, III. Medizinische Klinik Studienzentrale im MCC</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Saußele, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Herbart, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH (Krankenhaus St. Franziskus), Medizinische Klinik I (Klinik f. Hämatologie, Onkologie, Gastroentereologie)</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ullrich Graeven, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologische Gemeinschaftspraxis Pasing-Fürstenfeldbruck</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Zingerle, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>München</city>
        <zip>83177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Dreyling, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Med. Klinik A</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kerkhoff, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SHR Kliniken Landkreis Sigmaringen GmbH, Hämatologie u. Internistische Onkologie</name>
      <address>
        <city>Sigmaringen</city>
        <zip>72488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriele Käfer, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm; Klinik für Innere Medizin Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Buske, Prof. Dr.</last_name>
      <email>christian.buske@uni-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Rudolf Schlag, Björn Schöttker, Joachim Haas</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Schlag, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>'Alexandra' General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meletios A. Dimopoulos, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Christian Buske</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Waldenstrom Macroglobulinemia, Ibrutinib, Bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

